The SEC's lawsuit against Ripple Labs over the alleged $1.3 billion unregistered XRP sale may be nearing its end, with the agency potentially classifying XRP as a commodity rather than a security. This shift in stance could have significant implications for the future of XRP and the broader cryptocurrency industry.
Perspective Therapeutics, a clinical-stage biotechnology company developing targeted radiotherapy agents for cancer treatment, has shown promising results in its Phase 1/2a trials for melanoma and neuroendocrine tumors. The company's lead programs, VMT01/02 and VMT-α-NET, have demonstrated anti-tumor activity and a favorable safety profile, suggesting significant potential in the growing field of targeted radioligand therapy.
The Consumer Price Index (CPI) rose by 2.8% year-over-year in February, marking a slight moderation compared to January's 3% increase. While some categories like TVs and Sporting Goods saw price declines, others like Appliances and Pet Food experienced increases, suggesting that inflationary pressures may be easing.
UiPath shares plummeted 14% after the company reported lower-than-expected revenue guidance for the first quarter, despite exceeding earnings estimates for the fourth quarter. Investors reacted negatively to the weaker outlook, overshadowing the company's progress in AI-driven automation and acquisitions.
DocuSign exceeded analyst expectations in its fourth quarter, reporting revenue of $776.3 million and adjusted earnings per share of 86 cents. The company's strong performance was driven by continued growth in subscription revenue and billings, as well as the launch of its AI-powered agreement management platform, DocuSign IAM.